Lymphoma News – February edition

Catch up on the latest Lymphoma Australia news, events and lymphoma updates in our February 2018 e-news edition.

Read the February enewsletter here

This edition includes:

  • World Cancer Day: 4 February – get involved!
  • PBS Updates
  • Targeted Therapies – what is it?
  • Global Patient Survey is now open for your contributions
  • Updated patient resources now available – new Fact Sheets
  • Legs Out for Lymphoma walks – sign up for Brisbane on Sunday 25 March

Make sure you never miss an invitiation or update – sign up to recieve our newsletters straight to your inbox. Click here…

Share This

Contact Lymphoma Australia Today!

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.